Xencor reports phase 1 data for cancer drug XmAb819

젠코어가 항암제 XmAb819의 1상 데이터를 보고했으나 구체적인 효능과 안전성 결과가 제시되지 않아 주가 방향성은 중립적으로 판단됩니다.

AI CATALYST SCORE45 / 100Score computed by Sentinel V12

REFERENCE PRICENot measuredReference entry price at analysis time

Diagnosed At	Ticker	AI Score	Tier
2026-10-25 08:49:05	XNCR	45	Mid	View Report →
2026-07-17 20:52:11	XNCR	85	S-Class	View Report →
2026-07-17 13:18:44	XNCR	65	Mid	View Report →

XNCR Analysis History (Last 30 Days)